This study is a prospective, single-arm, phase II, single-center study. Patients with locally unresectable giant osteosarcoma masses who meet the criteria are enrolled in the experimental group, and all patients receive a single dose of 10Gy of implantable brachytherapy. Record treatment-related acute events during and after treatment. Follow up on survival and local control after treatment ends, marking the end of the trial treatment.
Pathological diagnosis of osteosarcoma;
Age range 12-70 years old;
The primary or metastatic lesion cannot be surgically removed based on clinical evaluation, and treatment with internal medicine multi line chemotherapy, targeted therapy, immunotherapy, etc. is ineffective;
ECOG physical fitness status is 0-1 points;
Local mass previously received radiation therapy;
Major surgery ≤ 4 weeks before enrollment;
Previous or concurrent malignant tumors (excluding malignant tumors that have been cured and have a cancer free survival of more than 5 years, such as basal cell carcinoma of the skin and papillary thyroid carcinoma);
Pregnant or lactating women;
Single group
brachytherapy
RadiationPatients with locally unresectable giant osteosarcoma masses who meet the criteria are enrolled in the experimental group, and all patients receive a single dose of 10Gy of implantable brachytherapy. Record treatment-related acute events during and after treatment. Follow up on survival and local control after treatment ends, marking the end of the trial treatment.
progression-free survival
6 months of progression-free survival
progression-free survival
12 months progression-free survival
progression-free survival
12 months of progression-free survival
OS
12 months of OS
Adverse reactions related to radiotherapy
Adverse reactions
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
